key: cord-0683213-sz9m6hnr authors: Jimeno, Cecilia; Anonuevo-Cruz, Ma. Cecille; Uy, Angelique Bea; Bacena, Adrian Oscar; Francisco, Mark David; Tiglao-Gica, Angelique Love; Bruno, Racquel; Corpuz, Diane Grace title: UP Philippine General Hospital Division of Endocrinology, Diabetes & Metabolism Consensus Recommendations for In-Patient Management of Diabetes Mellitus among Persons with COVID-19 date: 2020-05-16 journal: J ASEAN Fed Endocr Soc DOI: 10.15605/jafes.035.01.05 sha: 6f377b379b64e35adf58ce07dbbf2a8f8c3e3ddb doc_id: 683213 cord_uid: sz9m6hnr Diabetes mellitus (DM) is a known risk factor for morbidity and mortality among patients with COVID-19 based on recent studies. While there are many local and international guidelines on inpatient management of diabetes, the complicated pathology of the virus, the use of glucose-elevating drugs such as glucocorticoids, antivirals and even inotropes, and various other unique problems has made the management of in-hospital hyperglycemia among patients with COVID-19 much more difficult than in other infections. The objective of this guidance is to collate and integrate the best available evidence that has been published regarding in-patient management of diabetes among patients with COVID-19. A comprehensive review of literature was done and recommendations have been made through a consensus of expert endocrinologists from the University of the Philippines-Philippine General Hospital (UP-PGH) Division of Endocrinology, Diabetes and Metabolism. These recommendations are evolving as we continue to understand the pathology of the disease and how persons with diabetes are affected by this virus. The severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) is a novel coronavirus that was first recognized in Wuhan, China in December 2019. Since then, it has spread quickly and is now considered a global pandemic. Despite the many researches that have been published, much remains unknown regarding SARS-CoV-2 and its designated disease, COVID-19. Diabetes mellitus (DM) is a known risk factor for severe illness among patients with COVID- 19 . In a retrospective cohort study of confirmed COVID-19 patients in China, diabetes was identified as the second most common comorbidity, found in 7.4% of patients. 1 A meta-analysis of 12 studies also from China reported that diabetes was present in 10.3% of more than 2,000 patients with COVID-19, 2 which was similar to their 2013 national prevalence of 10.9%. 3 Diabetes was likewise a prognostic factor for ICU admission, acute respiratory distress syndrome (ARDS) (OR 2.34 [1.35-4 .05]), and mortality (OR 2.85 [1.35-6.05 ]. [4] [5] [6] Epidemiological studies of countries with high disease burden showed that the risk of dying from COVID-19 is up to 50% higher among persons with diabetes compared to those who do not have diabetes. 7 While there are many local and international guidelines on inpatient management of diabetes, the complicated pathology of the virus, the use of glucose-elevating drugs such as glucocorticoids, antivirals and even inotropes, and various other unique problems has made the management of in-hospital hyperglycemia among patients with COVID-19 much more difficult than in other infections. Coupled with these are the difficulties in feeding those who have COVID-19 due to the management of respiratory failure that involves putting the patient in a prone position. The objective of this guidance is to collate and integrate the best available evidence that has been published regarding in-patient management of diabetes among patients with COVID-19. A comprehensive review of literature was done and recommendations have been made through a consensus of expert endocrinologists from the University of the Philippines-Philippine General Hospital (UP-PGH) Division of Endocrinology, Diabetes and Metabolism. It is complacent to think that COVID-19 is just another infection that necessarily triggers higher stress conditions and the release of catecholamines and glucocorticoids, 1. What do we assess at the emergency room? • Routine point of care testing for blood sugar should be done for all patients with COVID-19 to rapidly identify new cases of diabetes and to assess blood sugar control; any random CBG >140 mg/ dl (>7.8 mmol/L) should routinely be monitored within the next 24 hours. • Urine or serum ketone determination, in all patients with known diabetes or those with admission glucose over 220 mg/dl (12 mmol/L), as COVID-19 infection causes ketosis or ketoacidosis, which may increase the length of hospital stay and mortality. 16 Baseline laboratory tests to determine glycemic control such as HbA1c (if without anemia or with acceptable hemoglobin levels), fasting blood sugar or random blood sugar should be obtained. Point-of-care testing by obtaining the capillary blood glucose level should be done upon admission. Other diagnostic examinations to determine the presence of DM-related complications should be requested such as creatinine with estimated glomerular filtration rate, urinalysis with urine albumin, glucose and ketones and 12-lead ECG. Some studies show development of ketosis and severe insulin resistance among patients with COVID-19 and diabetes, thus laboratory tests such as serum sodium, potassium, blood urea nitrogen, chloride and arterial blood gas are important and should be done, along with blood or urine ketones. Additionally, serum albumin, phosphorus and magnesium can be taken for complete nutritional assessment, as well as calcium to assess risk for arrhythmias. Coagulation profile may be warranted, leading to hyperglycemia and abnormal glucose variability. While it is true that the greater majority of those affected with SARS-COV-2 will have only minor illness and will likely have only mild perturbations of their blood sugar levels, it appears that there are emerging novel aspects of hyperglycemia among those with COVID-19. One of these unique features is the observation of very high insulin requirements among those with a severe course of the infection, even among those who are not on glucocorticoids. We have observed this even in the cohorts of patients whom we have seen at the PGH, necessitating high doses of insulin given intravenously. According to a recent publication in the Lancet, it appears that the extent of insulin resistance in patients with COVID-19 and diabetes appears to be disproportionate compared with critical illness from other conditions. 8 There are also reports of a greater incidence of diabetes emergencies among persons with diabetes and COVID-19. It is already established that the virus gains entry to cells through an endocrine pathway, the Angiotensin-Converting-enzyme-2 (ACE2) receptor. Cellular damage can be caused by both acute and chronic hyperglycemia, as the former causes the up-regulation of ACE2 expression facilitating viral entry. Chronic hyperglycemia, on the other hand, causes reduced expression of ACE2 potentially through glycosylation, making the cells vulnerable to the cell-damaging effects of the virus. ACE2 is recognized to have anti-inflammatory and anti-oxidant functions. 9 The pancreatic beta-cells are known to express the ACE2 receptors suggesting (although without yet direct human verification) that the COVID-19 infection can induce new-onset diabetes by beta-cell damage. This could potentially then cause insulin deficiency, explaining the observations of both the UK and Italian investigators of frequent cases of severe diabetic ketoacidosis (DKA) and even atypical ketosis among persons with Type 2 diabetes, at the time of hospital admission. [9] [10] [11] Finally, hypoglycemia (at least one episode of BG <3.9 mmol/L) has been noted in around 10.3% of patients with COVID-19 and diabetes in Wuhan, China. 12 Some of the risk factors for hypoglycemia may include the development of acute renal failure, interruptions in feeding whenever patients are put on prone position as part of the management of respiratory distress, and the use of chloroquine or hydroxychloroquine which are known to cause hypoglycemia as a side effect. This underscores the importance of routinely monitoring the capillary blood glucose of patients started on these drugs. 13 Hypoglycemia has been shown to mobilize pro-inflammatory monocytes and increase platelet reactivity, contributing to a higher cardiovascular mortality in patients with diabetes. 14 These mechanisms may interact with chronic inflammation, increase coagulation activity, further impair immune response and with potential direct pancreatic damage by SARS-CoV-2, may explain the underlying pathophysiological mechanisms contributing to the increased morbidity and mortality of COVID-19 in people with diabetes. 15 The satisfactory control of diabetes, with avoidance of both hyperglycemia and hypoglycemia is therefore critical in preventing morbidity and mortality among diabetics with COVID-19 infection. Vol. 35 No. 1 May 2020 since apart from COVID-19-related inflammatory processes, insulin resistance and Type 2 diabetes mellitus are associated with endothelial dysfunction, and enhanced platelet aggregation and activation. These abnormalities contribute to the development of a hypercoagulable prothrombotic state. 6 There is no reason to believe that the established guidelines and standard of care for the treatment of infections among patients with diabetes may not be extended to those who are diagnosed with COVID-19. In particular, the 2020 ADA Standards of Diabetes Care 19 recommends the following schemes for monitoring of blood glucose: a. In hospitalized patients with diabetes who are eating, glucose monitoring should be performed before meals and at bedtime; b. In those not eating, glucose monitoring is advised every 4-6 hours. c. More frequent blood glucose testing ranging from every 30 min to every 2 hours is the required standard for safe use of intravenous insulin. Special consideration must be taken for patients who have blood glucose values that are 250-300 mg/ dL (>15 mmol/); for those who are critically-ill in the intensive care unit, there may be a need to start an insulin drip using a standard protocol which would require hourly monitoring. Diabetes emergencies also need to be ruled out for these severely elevated values for which more dynamic drip protocols are needed (Section 5). Once blood sugar is controlled and glycemic targets achieved, CBG monitoring may be adjusted accordingly. Additionally, the Philippine Society of Endocrinology, Diabetes, and Metabolism (PSEDM), in their Position Statement published March 2020 20 recommends the following: a. Patients who have stable vital signs may be allowed to take their own blood glucose test while being visually monitored by a nurse or physician. b. When possible, the use of continuous glucose monitoring (CGM) is encouraged to help mitigate the exposure of healthcare workers to COVID-19 cases, provided regular calibration with the standard blood glucose testing is undertaken. The general treatment goals for patients with diabetes are to address or prevent acute glycemic decompensation, prevent or delay the development of microvascular and macrovascular disease complications, avoid adverse events like hypoglycemia, decrease mortality, and provide a smooth transition to outpatient care. The general target blood glucose levels for hospitalized patients is around 140 to 180 mg/dl (7.8 to 10 mmol/l). Blood glucose levels >180 mg/dl (10 mmol/l) may require an increase in insulin dose. 5.1 When caring for hospitalized patients with diabetes and COVID-19 (suspected, probable or confirmed), we recommend ROUTINE referral to endocrinology service or a specialized diabetes or glucose management team whenever possible. 19, 20 This is especially true for moderate and severe cases of COVID-19 where the hyperglycemia is more likely. 26 It is still unknown whether these mechanisms apply to COVID-19 and whether treatment with DPP4inhibitors could potentially influence the course of the infection. However, if these mechanisms are translatable to SARS-CoV-2, then the use of these agents could potentially reduce DPP-4 concentrations and thus, present as opportunities for its treatment. 27 These drugs are also generally safe and well tolerated, and can be continued even during the hospitalization. 7.1 Administration of insulin using prolonged "Sliding Scale" alone is NOT recommended as it is reactive to a pre-existing hyperglycemia and if improperly timed may lead to hypoglycemia. These oscillations are termed "glycemic variability." Both hyper-and hypoglycemia have been known to be pro-inflammatory and thus, may aggravate the already overactive inflammatory response in COVID-19. Coupled with this is the fact that large glycemic variability is per se predictive of high ICU mortality. 29 7.2 Generally, the ideal regimen should be a basalbolus regimen, with a long acting basal insulin analogue given once a day or NPH insulin given once to twice a day, plus rapid-acting or regular insulin given pre-meals. In starting insulin, calculate the today daily dose as follows: • Elderly (aged 70 years and above) and/or glomerular filtration rates less than 60 ml/ min: 0.2 to 0.3 U/kg of body weight per day • Adults with blood glucose concentration 7. There is some concern about these drugs because the DPP-4 enzyme has been identified in cell studies as a receptor for the human coronavirus-Erasmus Medical (ARDS, hyperinflammation) for exact titration, avoiding variable subcutaneous resorption, and commonly seen very high insulin consumption" 8 (Section 7.1). 8.1 Statins: There is also some concern for the use of statins, as its use has been associated with the up-regulation of the ACE2 receptor levels, and in fact this is the mechanism that has been used to explain the pleiotropic anti-inflammatory effect of this drug. Again, this upregulation may facilitate the entry of the virus. However, most of the experts across the world have recommended that statins should be continued among patients with diabetes and COVID-19 not only because of its long term benefit for cardiovascular disease reduction in established diabetes, but also because mechanistically its discontinuation may tip the balance towards a cytokine storm by causing rebound increases in the levels of IL-6 and IL-1. 8 8.2 Anti-hypertensives: The fact that the SARS-COV2 uses the ACE-2 receptor as the entry point inside the cells has created some concern over the use of ACE-inhibitors and Angiotensin Receptor Blockers (ARBs). However, there appears to be no definite evidence that the use of these drugs worsens the outcome for those who use it. This is the position of most expert groups including the European Society of Cardiology and the Heart Failure Society of America, American College of Cardiology, American Heart Association, and even the local Philippine Society of Hypertension. These organizations strongly recommend continuation of treatment with ACE inhibitors and angiotensin 2 receptor blockers unless there are contraindications such as shock or acute kidney injury. 30, 31 8.3 Anti-platelets: Low dose aspirin or clopidogrel is typically given to persons with diabetes who are at high risk of major adverse cardiovascular events. 32, 33 It is therefore reasonable that among those who are taking these drugs as maintenance medications, they should be continued during the hospitalization unless there are specific contraindications to their use especially among those with severe COVID-19 infections. 9.1 Identifying the critically ill patient (who is not diagnosed to be in Hyperglycemic Emergency) who may require an insulin drip protocol The following are the indications for those who may require an Insulin Drip: These recommendations are meant to be guides in managing patients with diabetes and COVID-19 infection. They are not meant to replace sound judgment and individualized therapy according to the specific patient circumstances. These guidelines are also a work in progress and feedback from other experts, scientists and clinicians are appreciated so that this manuscript can continue to be revised and improved. Finally, these recommendations are evolving as we continue to understand the pathology of the disease and how persons with diabetes are affected by this virus. www.asean-endocrinejournal.org Authors are required to accomplish, sign and submit scanned copies of the JAFES Author Form consisting of: (1) Authorship Certification, that authors contributed substantially to the work, that the manuscript has been read and approved by all authors, and that the requirements for authorship have been met by each author; (2) the Author Declaration, that the article represents original material that is not being considered for publication or has not been published or accepted for publication elsewhere, that the article does not infringe or violate any copyrights or intellectual property rights, and that no references have been made to predatory/ suspected predatory journals; (3) the Author Contribution Disclosure, which lists the specific contributions of authors; and (4) the Author Publishing Agreement which retains author copyright, grants publishing and distribution rights to JAFES, and allows JAFES to apply and enforce an Attribution-Non-Commercial Creative Commons user license. Authors are also required to accomplish, sign, and submit the signed ICMJE form for Disclosure of Potential Conflicts of Interest. For original articles, authors are required to submit a scanned copy of the Ethics Review Approval of their research as well as registration in trial registries as appropriate. For manuscripts reporting data from studies involving animals, authors are required to submit a scanned copy of the Institutional Animal Care and Use Committee approval. For Case Reports or Series, and Images in Endocrinology, consent forms, are required for the publication of information about patients; otherwise, appropriate ethical clearance has been obtained from the institutional review board. Articles and any other material published in the JAFES represent the work of the author(s) and should not be construed to reflect the opinions of the Editors or the Publisher. www.asean-endocrinejournal.org Protocol for management of adult patients with DKA or HHS. DKA diagnostic criteria: blood glucose 250 mg/dl, arterial pH 7.3, bicarbonate 15 mEq/l, and moderate ketonuria or ketonemia. HHS diagnostic criteria: serum glucose >600 mg/dl, arterial pH >7.3, serum bicarbonate >15 mEq/l, and minimal ketonuria and ketonemia. †15-20 ml/kg/h; ‡serum Na should be corrected for hyperglycemia (for each 100 mg/dl glucose 100 mg/dl, add 1.6 mEq to sodium value for corrected serum value). (Adapted from ref. 13.) Bwt, body weight; IV, intravenous; SC, subcutaneous. Clinical characteristics of coronavirus disease 2019 in China Prevalence and impact of diabetes among people infected with SARS-CoV-2 Prevalence and control of diabetes in Chinese adults Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study COVID-19 and Italy: What next? Practical recommendations for the management of diabetes in patients with COVID-19 The sweeter side of ACE2: Physiological evidence for a role in diabetes Characterization of ACE and ACE2 expression within different organs of the NOD mouse Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review Effect of hypoglycemia on inflammatory responses and the response to low-dose endotoxemia in humans COVID-19 and diabetes: Knowledge in progress COncise adVice on Inpatient Diabetes (COVID: Diabetes): FRONT DOOR GUIDANCE COVID-19 infection may cause ketosis and ketoacidosis High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring) Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2020 Philippine Society of Endocrinology Diabetes and Metabolism. Position Statement on COVID-19 Infection and Diabetes COVID-19 outbreak: Guidance for people with diabetes Intensive versus conventional glucose control in critically ill patients ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection Guidance for Nutrition Therapy of Adults with Confirmed or Suspected COVID-19 Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC COVID-19 and diabetes: Can DPP4 inhibition play a role? Management of hyperglycemia in hospitalized patients in non-critical care setting: An endocrine society clinical practice guideline Higher glycemic variability within the first day of ICU admission is associated with increased 30-day mortality in ICU patients with sepsis HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 Position Statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. European Society of Cardiology Aspirin and diabetes mellitus in primary prevention: The endless conundrum Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020 Efficacy and safety of the UP-PGH endocrine insulin infusion protocol in controlling hyperglycemia in UP-PGH Medical Intensive Care Unit and Central Intensive Care Unit Evaluation of effectiveness and safety of an ICU insulin infusion protocol The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The perspectives of clinical immunologists from China World Health Organization. WHO Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected Philippine Society of Allergy Asthma and Immunology. A review of immunomodulators as therapeutic interventions for moderate to severe COVID-19 infections Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review Hyperglycemic crises in adult patients with diabetes: A consensus statement from the American Diabetes Association The authors thank the following: Faculty of the UP-PGH Division of Endocrinology: Emeritus Professor Mary Anne VA Lim- Appendix B.2. European Society of Parenteral and Enteral Nutrition Practical Guidance for Nutritional Management of Individuals with SARS-CoV-2 Infection (Adapted) 23 Nutritional management in individuals at risk for severe COVID-19, in subjects suffering from COVID-19, and in COVID-19 ICU patients requiring ventilation. For details, see text.* MUST Criteria: is a five-step screening tool to identify adults who are malnourished, at risk of malnutrition (undernutrition), or obese. It can be downloaded for free at this website: www.bapen.org.uk ** NRS-2002 is a method endorsed by the ESPEN, to detect the presence of undernutrition and the risk of developing undernutrition in the hospital setting. It contains the nutritional components of MUST, and in addition, a grading of severity of disease as a reflection of increased nutritional requirement.